首页|叶酸联合阿仑膦酸钠对绝经后骨质疏松患者骨密度、骨代谢指标和纤维细胞生长因子水平的影响

叶酸联合阿仑膦酸钠对绝经后骨质疏松患者骨密度、骨代谢指标和纤维细胞生长因子水平的影响

扫码查看
目的:探讨绝经后骨质疏松患者采用叶酸与阿仑膦酸钠联合治疗对其纤维细胞生长因子、骨代谢及骨密度指标的影响.方法:采用抽签法将 2020 年4 月至 2022 年6 月我科收治的绝经后骨质疏松患者 106 例随机分为两组(n=53),对照组口服阿仑膦酸钠 10 mg、硫辛酸 0.6 g,1 次·d-1,观察组口服阿仑膦酸钠 10 mg、叶酸 2 片,1次·d-1,治疗6 m后采用骨密度测定器测定股骨大转子、股骨颈、股骨干及第二腰椎-第四腰椎(L2-L4)骨密度,采用酶联免疫吸附法测定保护素(Osteoprotegerin,OPG)、核因子 кB受体激活因子配体(Receptor activator of NF-KB ligand,RANKL)、I型胶原交联C-末端肽(type Ⅰ C-tenninal cross linked peptide,CTX-1)和纤维细胞生长因子(Fibroblast growth facto,FGF)水平,采用电化学发光免疫分析法检测骨钙素(Bone glaprotein,BGP)水平,采用随访法观察各患者不良反应.结果:与治疗前相比,各治疗组的股骨大转子、股骨颈、股骨干及L2-L4 骨密度、OPG及BGP明显升高(P<0.05),其中观察组升高更显著(P<0.05);与治疗前比,各治疗组RANKL、CTX-1、FGF-23和FGF-21 明显降低(P<0.05),其中观察组降低更明显(P<0.05),两组各不良反应无统计学差异(P>0.05).结论:绝经后骨质疏松患者口服阿仑膦酸钠联合叶酸治疗,可有效调节其FGF水平,改善其骨代谢和骨密度情况,不良反应较少.
Effects of folic acid combined with alendronate sodium on bone mineral density,bone metabolism indexes,and fibrocyte growth factor levels in postmenopausal patients with osteoporosis
Objective:To investigate the effects of folic acid combined with alendronate sodium on fibrocyte growth factor,bone metabolism,and bone mineral density in postmenopausal patients with osteoporosis.Method:A total of 106 postmenopausal osteoporosis patients admitted to our department from April 2020 to June 2022 were randomly divided into two groups(n=53).The control group received alendronate sodium 10 mg and lipoic acid 0.6 g once·d-1,while the observation group received alendronate sodium 10 mg and folic acid 2 tablets once·d-1.After 6 m of treatment,bone densitometry was used to determine the bone density of the femoral greater trochanter,femoral neck,femoral shaft,and the second and fourth lumbar vertebra(L2-L4),and enzyme-linked immunosorbent assay was used to determine Osteoprotegerin(OPG),receptor activator of NF-KB ligand(RANKL),type Ⅰ C-tenninal cross-linked peptide(CTX-1),and fibroblast growth factor(FGF)levels.Bone glaprotein(BGP)level was detected by electrochemiluminescence immunoassay.Follow-up was performed to observe the adverse reactions in each patient.Results:Compared with before treatment,bone density,OPG,and BGP of the femoral greater trochanter,femoral neck,femoral shaft,and L2-L4 were significantly increased in all treatment groups(P<0.05),especially in the observation group(P<0.05).Compared with before treatment,RANKL,CTX-1,FGF-23,and FGF-21 in the treatment groups were significantly decreased(P<0.05),and the decrease was more significant in the observation group(P<0.05),there was no statistical difference in adverse reactions between the two groups(P>0.05).Conclusion:Oral treatment of alendronate sodium combined with folic acid can effectively regulate FGF levels,and improve bone metabolism and bone mineral density in postmenopausal patients with osteoporosis,with fewer adverse reactions.

Postmenopausal osteoporosisAlendronate sodiumFibroblast growth factorBone metabolismBone density

冯培红、王欢欢、单帅

展开 >

郑州大学附属郑州中心医院内分泌科,河南 郑州 450000

绝经后骨质疏松 阿仑膦酸钠 纤维细胞生长因子 骨代谢 骨密度

2024

四川生理科学杂志
四川省生理科学会

四川生理科学杂志

影响因子:0.575
ISSN:1671-3885
年,卷(期):2024.46(2)
  • 10